CLINICAL TRIALS PROFILE FOR TECHNETIUM TC-99M PYROPHOSPHATE KIT

All Clinical Trials for TECHNETIUM TC-99M PYROPHOSPHATE KIT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03040427 ↗	The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis	Terminated	Avid Radiopharmaceuticals	Phase 4	2017-01-01	The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.
NCT03040427 ↗	The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis	Terminated	The Cleveland Clinic	Phase 4	2017-01-01	The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.
NCT03702829 ↗	24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients	Active, not recruiting	Brigham and Women's Hospital	Phase 2	2019-02-28	Transthyretin is a protein produced in the liver that transports thyroid hormone and vitamin A. A single substitution of an amino acid in the structure of TTR can result in a relatively unstable protein, the breakdown products of which (predominantly monomers) aggregate abnormally and produce proteinaceous deposits in nerves and the heart. These deposits are known as amyloid and produce progressive nerve and heart damage. Amyloidosis due to a mutant TTR is usually an autosomal dominant and hence is a familial condition. Wild-type TTR is also capable of producing amyloid deposits which predominantly involves the heart (rather than the nervous system) resulting in a progressive decrease in cardiac function with increasing signs of heart failure. This study aims to determine whether subcutaneous injection of an antisense oligonucleotide drug, known as inotersen, that has been specifically designed to reduce production of the protein transthyretin by the liver, can slow or stop the progression of TTR amyloid cardiomyopathy as compared to historical controls, using advanced echocardiography and cardiac MRI. The study also aims to determine the tolerability and safety of this drug when administered over a 24-month period to patients with TTR amyloid cardiomyopathy.

Clinical Trial Conditions for TECHNETIUM TC-99M PYROPHOSPHATE KIT

Condition Name

Condition Name for TECHNETIUM TC-99M PYROPHOSPHATE KIT
Intervention	Trials
Amyloidosis	1
Cardiac Amyloidosis	1

Condition MeSH

Condition MeSH for TECHNETIUM TC-99M PYROPHOSPHATE KIT
Intervention	Trials
Amyloidosis	2
Cardiomyopathies	1

Clinical Trial Locations for TECHNETIUM TC-99M PYROPHOSPHATE KIT

Trials by Country

Trials by Country for TECHNETIUM TC-99M PYROPHOSPHATE KIT
Location	Trials
United States	2

Trials by US State

Trials by US State for TECHNETIUM TC-99M PYROPHOSPHATE KIT
Location	Trials
Massachusetts	1
Ohio	1

Clinical Trial Progress for TECHNETIUM TC-99M PYROPHOSPHATE KIT

Clinical Trial Phase

Clinical Trial Phase for TECHNETIUM TC-99M PYROPHOSPHATE KIT
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TECHNETIUM TC-99M PYROPHOSPHATE KIT
Clinical Trial Phase	Trials
Active, not recruiting	1
Terminated	1

Clinical Trial Sponsors for TECHNETIUM TC-99M PYROPHOSPHATE KIT

Sponsor Name

Sponsor Name for TECHNETIUM TC-99M PYROPHOSPHATE KIT
Sponsor	Trials
Avid Radiopharmaceuticals	1
The Cleveland Clinic	1
Brigham and Women's Hospital	1

Sponsor Type

Sponsor Type for TECHNETIUM TC-99M PYROPHOSPHATE KIT
Sponsor	Trials
Other	2
Industry	1